Arkolith/Insider Trading/FBRX/Form 4

Wagner Paul A.

See Remarks, DirectorForte Biosciences, Inc. (FBRX) · full profile →Form 4 · filed Jan 3, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 1, 2024Tax withholding(F)4K$0.82$3K1.9M
Jan 1, 2024Option exercise(M)31K—$01.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 1, 2024Option exercise(M)31K—$0375K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-24-000316) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML